Prescribing information for Wegovy and Zepbound lists nausea, vomiting, abdominal pain, reflux-related symptoms, bloating, and abdominal distension among common or reported adverse reactions
25 Revenue Erosion: In Q2 2024, Novo Nordisk reported that sales growth slowed sharply due to competition from Lilly and compounded copycat drugs, causing a significant dip in stock price
In one clinical trial , 86% of participants without type 2 diabetes lost at least 5% of their body weight after 68 weeks but that also means nearly 14% of people lost less than that
Smarter Support: Vor allem im hektischen Alltag kann die Auswahl nhrstoffreicher Lebensmittel zur Challenge werden
After this offering, the holders of an aggregate of shares of our outstanding common stock as of December 31, 2019 will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders
The arrival of orforglipron represents a significant step toward making effective weight management accessible to a broader population